As the only tertiary care medical center in Vermont, the University of Vermont Larner College of Medicine’s Division of Neurosurgery provides comprehensive surgical management of disorders of the brain, spinal cord and peripheral nervous system. Since the division's establishment in 1948, we have been committed to translating leading-edge research into improved patient care.

Residents

Medical students and neurosurgery residents participate in a variety of research activities and provide care and an array of treatment options for patients who have brain and spinal disease. By facilitating critical thinking, we advance the knowledge needed to treat neurologic disorders and enhance the quality of clinical care.


 

Academic and Clinical Excellence

Surgery

As physicians and scientists, the Division of Neurosurgery faculty brings intellectual curiosity, scientific rigor, and fundamental concern to our patients, our trainees, our colleagues, and the communities we serve in northern New England. 

We advance knowledge and innovation, and enhance efficiency through clinical, translational, and biomedical research studies designed to improve the care of patients with neurologic disease. We are dedicated to patient-and family-centric treatment of individuals with neurologic disease, and to developing the next generation of neurosurgical physicians. The UVM Neurosurgery Residency Program if fully accredited by ACGME and committed to training future leaders in the field to be outstanding clinicians, active investigators and experienced educators.


Surgery News

Ahern Featured in Healio/HemOnc Today Article on Medications Associated with Breast Cancer

August 16, 2019 by Heather McCabe

(AUGUST 2, 2019) Healio.com highlighted research conducted by Assistant Professor of Surgery Thomas P. Ahern, Ph.D., M.P.H and colleagues in an article, titled "Certain medications linked to increased breast cancer risk."
(AUGUST 2, 2019) Healio.com highlighted research conducted by Assistant Professor of Surgery Thomas P. Ahern, Ph.D., M.P.H., and colleagues in an article, titled "Certain medications linked to increased breast cancer risk." The piece summarizes an study published by Ahern and colleagues in the Journal of Clinical Oncology on phthalate exposure and breast cancer incidence. Ahern wrote that “Preclinical evidence suggests that some phthalates promote breast tumor growth through ER signaling. Estrogen-independent breast cancer promotion mechanisms have also been reported for phthalates, as have antiestrogenic effects.”
Read the full article in Healio here >>. 
Read the study in Journal of Clinical Oncology here>>.